Skip to main content

Juvenile Idiopathic Arthritis clinical trials at UCSF

4 in progress, 3 open to eligible people

Showing trials for
  • Adalimumab in JIA-associated Uveitis Stopping Trial

    open to eligible people ages 2 years and up

    The proposed study is a stratified, block-randomized, double-masked, controlled trial to determine the feasibility of discontinuing adalimumab treatment in patients with quiescent uveitis associated with juvenile idiopathic arthritis (JIA) or chronic anterior uveitis (CAU).

    San Francisco, California and other locations

  • Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)

    open to eligible people ages 2-16

    This is a research study to test whether a once-weekly injection of abatacept will prevent the progression of Juvenile Idiopathic Arthritis (JIA) to a more severe form. To evaluate the effectiveness of a 24-week course of treatment with abatacept plus usual care versus usual care to prevent polyarthritis (≥5 joints), uveitis, or treatment with other systemic medication within 18 months of randomization in children with recent-onset limited JIA.

    San Francisco, California and other locations

  • Transcutaneous Vagus Nerve Stimulation (tcVNS) in JIA

    open to eligible people ages 5-18

    The study is a multicenter, double-blind, sham-controlled trial to evaluate the safety and effectiveness of tcVNS on pain and inflammation associated with JIA. tcVNS is administered with a device that gives off mild electrical impulses through the skin to stimulate the vagus nerve. Part of the vagus nerve and its branches are located in the head and neck. For this study, the impulses will be administered in areas overlying the vagus nerve using a small electrode. The electrode helps to conduct the stimulation through the skin. This stimulation triggers a chemical response through the nerves and has been found to be effective in reducing pain and inflammation in several diseases. The primary objective of this study is to determine the effect of tcVNS on JIA ACR 50 in participants with active JIA. The components of the active and sham tcVNS devices, utilizing the Roscoe Medical TENS 7000, have been FDA 510(k)-cleared and have been determined by the IRB to be a nonsignificant risk device.

    San Francisco, California and other locations

  • Pediatric Arthritis Study of Certolizumab Pegol

    Sorry, in progress, not accepting new patients

    A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).

    San Francisco, California and other locations

Our lead scientists for Juvenile Idiopathic Arthritis research studies include .

Last updated: